Anthem Commercial names its first preferred denosumab biosimilars
From November 1, Bildyos and Enoby join Prolia, and Bilprevda and Xtrenbo join Xgeva. Anthem's Medicare tables did not follow, and one Anthem list has not caught up.
The short version
For Anthem commercial members, four denosumab biosimilars became preferred on November 1. In Anthem's Medicare tables, the preferred products did not change: Prolia and Xgeva are still the only ones. Prolia and Xgeva are preferred in every Anthem document we checked, so they remain the safe choice when you are unsure which one governs.
Osteoporosis: the Prolia family
| Anthem table | Preferred | Non-preferred |
|---|---|---|
| Commercial medical benefit (from Nov 1) | Prolia, Bildyos, Enoby | Boncresa, Bosaya, Conexxence, Jubbonti, Ospomyv, Osvyrti, Ponlimsi, Stoboclo |
| Medicare medical benefit (from Nov 1) | Prolia | Bildyos, Boncresa, Bosaya, Conexxence, Enoby, Jubbonti, Ospomyv, Osvyrti, Ponlimsi, Stoboclo |
The Medicare row's November 1 update adds Ponlimsi to the non-preferred list; the preferred product is unchanged.
Oncology and metabolic bone disease: the Xgeva family
| Anthem table | Preferred | Non-preferred |
|---|---|---|
| Commercial medical benefit (from Nov 1) | Xgeva, Bilprevda, Xtrenbo | Aukelso, Bomyntra, Jubereq, Osenvelt, Oziltus, Wyost, Xbryk |
| Medicare medical benefit (from Jul 1) | Xgeva | Aukelso, Bilprevda, Bomyntra, Jubereq, Osenvelt, Oziltus, Wyost, Xbryk, Xtrenbo |
Neither policy lists preferred products for Anthem Medicaid.
Same payer, opposite answers
Bildyos and Enoby are now preferred in Anthem's commercial table and non-preferred in its Medicare table. Bilprevda and Xtrenbo are split the same way. A clinic that standardizes on one denosumab biosimilar for "Anthem" will be right for one line of business and wrong for the other. Match the order to the patient's plan, not just the payer's name.
One Anthem list has not caught up
Anthem also publishes a separate commercial Medical Specialty Pharmacy Drug List. When we last checked it, on November 1, it had not been reissued since November 2025 and still named Prolia and Xgeva as the only preferred denosumab products. It does not mention Bildyos, Enoby, Bilprevda or Xtrenbo at all. Prolia and Xgeva are preferred under every document. Before relying on one of the new biosimilars, confirm with Anthem which list applies to the member's plan.
Getting a non-preferred product approved
Both policies list one route for a non-preferred product: an allergy, severe intolerance or, in the Xgeva policy, a serious adverse reaction to an inactive ingredient in a preferred product, where the non-preferred product does not carry the same problem. The osteoporosis policy also requires a trial of a preferred product first, and says convenience is not a reason for approval. Both policies note that the preferred-product requirement applies where the member's benefit plan includes it.
Sources: Anthem Medical Drug Clinical Criteria CC-0027, Denosumab for Osteoporosis and CC-0310, Denosumab for Metabolic Bone Disease, both published October 27, 2026. Summarized by Beacana; confirm with the payer before relying on it for a specific authorization.